Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis

Next Previous
Search
Trial Profile

A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ACT-2
  • Sponsors Centocor; Janssen Biotech

    • Most Recent Events

    • 12 Jun 2018 Results of individual participant data (IPD) pooled analysis of five trials of infliximab and golimumab in UC, to evaluate whether concomitant use of 5-Aminosalicylates modifies clinical outcomes, were published in the American Journal of Gastroenterology.
    • 05 Jun 2018 Results of a pooled analysis of ACCENT-I, SONIC, ACT-1, and ACT-2 (n=1205) assessing the association between obesity and response to infliximab, published in the American Journal of Gastroenterology
    • 31 Mar 2010 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top